Pharmacogenetic testing for DPYD and UGT1A1 gene variants could cost-effectively prevent severe chemotherapy-related toxicity, but there are barriers to its uptake, two research teams reported at the 2021 Gastrointestinal Cancers Symposium.
“Pharmacogenetic, or PGx, variants in the DPYD and UGT1A1 genes are known to be associated with fluoropyrimidine and irinotecan toxicity, respectively. PGx testing prior to starting chemotherapy has been proposed as a way to safely guide the dosing of